Serial changes in the expression of breast cancer-related proteins in response to neoadjuvant chemotherapy

Annals of Oncology

Volumn 22, Issue 8, 2011, Pages 1748-1754

  Chuah, B Y S ^a   Putti, T ^a   Salto Tellez, M ^a   Charlton, A ^a   Iau, P ^a   Buhari, S A ^a   Wong, C I ^a   Tan, S H ^a   Wong, A L A ^a   Chan, C W ^a   Goh, B C ^a,b   Lee, S C ^a,b  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Breast cancer; Changes; Chemotherapy; COX 2; Neoadjuvant

Indexed keywords

CYCLOOXYGENASE 2; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 79961014486     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq755     Document Type: Article

References (34)

1. Veronesi U, Boyle P, Goldhirsch A et al. Breast cancer. Lancet 2005; 365: 1727-1741.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
3. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685.
4. Spizzo G, Gastl G, Wolf D et al. Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer 2003; 88: 574-578.
5. Magkou C, Nakopoulou L, Zoubouli C et al. Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas. Breast Cancer Res 2008; 10: R49.
6. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51.
7. de Azambuja E, Cardoso F, de Castro G Jr, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007; 96: 1504-1513.
8. Bonnefoi H, Diebold-Berger S, Therasse P et al. Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? Ann Oncol 2003; 14: 406-413.
9. Shim JY, An HJ, Lee YH et al. Overexpression of cyclooxygenase-2 is associated with breast carcinoma and its poor prognostic factors. Mod Pathol 2003; 16: 1199-1204.
10. Putti TC, To KF, Hsu HC et al. Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicentre immunohistochemical study in the Asia-Pacific region. Histopathology 2002; 41: 144-151.
11. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-2795.
12. Linn SC, Pinedo HM, van Ark-Otte J et al. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer 1997; 71: 787-795.
13. Chang J, Ormerod M, Powles TJ et al. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 2000; 89: 2145-2152.
14. Faneyte IF, Schrama JG, Peterse JL et al. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 2003; 88: 406-412.
15. Tsujii M, Kawano S, Tsuji S et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-716.
16. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 2000; 19: 19-27.
17. Sheng H, Shao J, Morrow JD et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998; 58: 362-366.
18. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997; 94: 3336-3340.
19. Rolland PH, Martin PM, Jacquemier J et al. Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 1980; 64: 1061-1070.
20. Loo WT, Sasano H, Chow LW. Effects of capecitabine and vinorelbine on cell proliferation, metabolism and COX2 and p16 expression in breast cancer cell lines and solid tumour tissues. Biomed Pharmacother 2007; 61: 596-600.
21. Ferrandina G, Ranelletti FO, Martinelli E et al. Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer. BMC Cancer 2006; 6: 182.
22. Gasparini G, Longo R, Sarmiento R, Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol 2003; 4: 605-615.
23. Sano H, Kawahito Y, Wilder RL et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995; 55: 3785-3789.
24. Hida T, Yatabe Y, Achiwa H et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 58: 3761-3764.
25. Uchida K, Schneider S, Yochim JM et al. Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 2005; 11: 3363-3368.
26. Fabi A, Metro G, Papaldo P et al. Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. Cancer Chemother Pharmacol 2008; 62: 717-725.
27. Lipton A, Campbell-Baird C, Witters L et al. Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer. J Clin Gastroenterol 2010; 44: 286-288.
28. O'Kane SL, Eagle GL, Greenman J et al. COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines. Lung Cancer 2010; 67: 160-165.
29. Csiki I, Morrow JD, Sandler A et al. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel. Clin Cancer Res 2005; 11: 6634-6640.
30. Govindan R, McLeod H, Mantravadi P et al. Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. Oncology (Williston Park) 2004; 18: 18-21.
31. Pai R, Soreghan B, Szabo IL et al. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002; 8: 289-293.
32. Shigemasa K, Tian X, Gu L et al. Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas. Int J Oncol 2003; 22: 99-105.
33. Penault-Llorca F, Abrial C, Raoelfils I et al. Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist 2008; 13: 1235-1245.
34. De Pas T, Pelosi G, de Braud F et al. Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare. J Clin Oncol 2004; 22: 4966-4970.